Clinical trial
A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer
NCT00125372 is registered in ClinicalTrials.gov with Dartmouth-Hitchcock Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- December 31, 2005
- Completion date
- August 31, 2010
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.